Regulation of ET: Pulmonary release of ET contributes to increased plasma ET levels and vasoconstriction in CHF

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 278, Issue 4 47-4, 2000, Pages

  Kjekshus, Harald ^a   Smiseth, Otto A ^a   Klinge, Randi ^a   Øie, Erik ^a   Hystad, Marit E ^a   Attramadal, Håvard ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Heart failure; Pacing; Receptors; Ribonucleic acid; Swine

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HEART HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE BINDING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SWINE; VASOCONSTRICTION;

EID: 0034010404     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.2000.278.4.h1299     Document Type: Article

References (65)

1. Arai H, Hori S, Aramori I, Ohkubo H, and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730-732, 1990.
2. Arai M, Yoguchi A, Iso T, Takahashi T, Imai S, Murata K, and Suzuki T. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol Heart Circ Physiol 268: H2084-H2091, 1995.
3. Armstrong PW, Stopps TP, Ford SE, and de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation 74: 1075-1084, 1986.
4. Borgeson DD, Grantham JA, Williamson EE, Luchner A, Redfield MM, Opgenorth TJ, and Burnett JC Jr. Chronic oral endothelin type A receptor antagonism in experimental heart failure. Hypertension 31: 766-770, 1998.
5. Cannan CR, Burnett JC Jr, Brandt RR, and Lerman A. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. Circulation 92: 3312-3317, 1995.
6. Cody RJ, Haas GJ, Binkley PF, Capers Q, and Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85: 504-509, 1992.
7. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, and Dargie HJ. Pulmonary and systemic responses to exogenous endothelin-1 in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 31: S290-S293, 1998.
8. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, Bonan R, and Crepeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 135: 614-620, 1998.
9. Dupuis J, Goresky CA, and Stewart DJ. Pulmonary removal and production of endothelin in the anesthetized dog. J Appl Physiol 76: 694-700, 1994.
10. Dupuis J, Rouleau JL, and Cernacek P. Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 98: 1684-1687, 1998.
11. Dupuis J, Stewart DJ, Cernacek P, and Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 94: 1578-1584, 1996.
12. Elshourbagy NA, Lee JA, Korman DR, Nuthalaganti P, Sylvester DR, Dilella AG, Sutiphong JA, and Kumar CS. Molecular cloning and characterization of the major endothelin receptor subtype in porcine cerebellum. MoI Pharmacol 41: 465-473, 1992.
13. Fraccarollo D, Hu K, Galuppo P, Gaudron P, and Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation 96: 3963-3973, 1997.
14. Hall C and Karlberg BE. Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition. Res Exp Med (Berl) 186: 387-395, 1986.
15. Huntington K, Picard P, Moe G, Stewart DJ, Albernaz A, and Monge JC. Increased cardiac and pulmonary endothelin-1 mRNA expression in canine pacing-induced heart failure. J Cardiovasc Pharmacol 31: S424-S426, 1998.
16. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, and Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 86: 2863-2867, 1989.
17. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, and Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 92: 398-403, 1993.
18. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, Oechslin E, Schmitt R, Jones R, and Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346: 732-736, 1995.
19. Kjekshus H, Risoe C, Scholz T, and Smiseth OA. Regulation of hepatic blood volume: contributions from active and passive mechanisms during catecholamine and sodium nitroprusside infusion. Circulation 96: 4415-4423, 1997.
20. Klinge R, Djoseland O, Karlberg BE, and Hall C. Cardiac secretion of atrial and brain natriuretic peptides in acute ischaemic heart failure in pigs: effect of angiotensin II receptor antagonism. Clin Physiol 17: 389-400, 1997.
21. B receptor-mediated clearance of endothelin-1? Life Sci 62: 185-193, 1998.
22. Kobayashi T, Miyauchi T, Sakai S, Yamaguchi I, Goto K, and Sugishita Y. Endothelin-converting enzyme and angiotensin-converting enzyme in failing hearts of rats with myocardial infarction. J Cardiovasc Pharmacol 31: S417-S420, 1998.
23. Kribbs SB, Clair MJ, Krombach RS, Hendrick JW, Thomas PB, Keever AT, Houch WV, Mukherjee R, and Spinale FG. Pulmonary hemodynamics and endothelin levels in pacing-induced heart failure: during rest and exercise. J Card Fail 3: 263-270, 1997.
24. Lerman A, Hildebrand FL Jr, Aarhus LL, and Burnett JC Jr. Endothelin has biological actions at pathophysiological concentrations. Circulation 83: 1808-1814, 1991.
25. Lerman A, Kubo SH, Tschumperlin LK, and Burnett JC Jr. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 20: 849-853, 1992.
26. Maguire JJ and Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 115: 191-197, 1995.
27. McConnell PI, Wang W, and Zucker IH. Effects of an orally effective endothelin-A receptor antagonist in dogs with pacing-induced heart failure. Nebr Med J 81: 349-355, 1996.
28. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, and Morton JJ. Plasma endothelin in chronic heart failure. Circulation 85: 1374-1379, 1992.
29. A-receptor antagonist. Circulation 96: 1593-1597, 1997.
30. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, and Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96: 1976-1982, 1997.
31. Mundhenke M, Schwartzkopff B, Kostering M, Deska U, Klein RM, and Strauer BE. Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy. Heart 81: 278-284, 1999.
32. Neri Serneri GG, Cecioni I, Migliorini A, Vanni S, Galanti G, and Modesti PA. Both plasma and renal endothelin-1 participate in the acute cardiovascular response to exercise. Eur J Clin Invest 27: 761-766, 1997.
33. Neri Serneri GG, Modesti PA, Cecioni I, Biagini D, Migliorini A, Costoli A, Colella A, Naldoni A, and Paoletti P. Plasma endothelin and renal endothelin are two distinct systems involved in volume homeostasis. Am J Physiol Heart Circ Physiol 268: H1829-H1837, 1995.
34. Nishimura J, Aoki H, Chen X, Shikasho T, Kobayashi S, and Kanaide H. Evidence for the presence of endothelin ETA receptors in endothelial cells in situ on the aortic side of porcine aortic valve. Br J Pharmacol 115: 1369-1376, 1995.
35. Ogilvie RI and Zborowska-Sluis D. Effect of chronic rapid ventricular pacing on total vascular capacitance. Circulation 85: 1524-1530, 1992.
36. Ogilvie RI and Zborowska-Sluis D. Vascular capacitance and cardiac output in pacing-induced canine models of acute and chronic heart failure. Can J Physiol Pharmacol 73: 1641-1650, 1995.
37. Øie E, Bjornerheim R, Grogaard HK, Kongshaug H, Smiseth OA, and Attramadal H. Endothelin receptor antagonism, myocardial gene expression and ventricular remodeling during congestive heart failure in rats. Am J Physiol Heart Circ Physiol 275: H868-H877, 1998.
38. Øie E, Vinge LE, Tonnessen T, Grogaard HK, Kjekshus H, Christensen G, Smiseth OA, and Attramadal H. Transient, isopeptide-specific induction of myocardial endothelin-1 mRNA in congestive heart failure in rats. Am J Physiol Heart Circ Physiol 273: H1727-H1736, 1997.
39. Omland T, Lie RT, Aakvaag A, Aarsland T, and Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89: 1573-1579, 1994.
40. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, and Davenport AP. Expression of endothelin peptides and mRNA in human heart. Clin Sci 90: 37-46, 1996.
41. Price HL, Deutsch S, Marshall BE, Stephen GW, Behar MG, and Neufeld GR. Hemodynamic and metabolic effects of hemorrhage in man, with particular reference to the splanchnic circulation. Circ Res 18: 469-474, 1966.
42. Rodeheffer RJ, Lerman A, Heublein DM, and Burnett JC Jr. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 67: 719-724, 1992.
43. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, and Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384: 353-355, 1996.
44. Sakai S, Miyauchi T, Sakurai T, KasuyaY, Ihara M, Yamaguchi I, Goto K, and Sugishita Y. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93: 1214-1222, 1996.
45. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, Goto K, and Sugishita Y. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. JAm Coll Cardiol 28: 1580-1588, 1996.
46. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Natare 348: 732-735, 1990.
47. Sirvio ML, Helin K, Stewen P, Tikkanen I, and Fyhrquist F. Endothelin-1 in heart and pulmonary tissue in experimental heart failure. Blood Press 6: 250-255, 1997.
48. 125I-endothelin in the rat: importance of pulmonary clearance. Biochem Biophys Res Commun 167: 1191-1195, 1990.
49. Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, and Carabello BA. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol Heart Circ Physiol 259: H218-H229, 1990.
50. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, and Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation 95: 1918-1929, 1997.
51. Stewart DJ, Cernacek P, Costello KB, and Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85: 510-517, 1992.
52. Sutsch G, Bertel O, and Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 10: 717-725, 1997.
53. Takai K, Ito H, Sahashi T, Wada H, Segawa T, and Hirakawa S. Differing actions of endothelin-1 on canine systemic resistance and capacitance vessels. Jpn Circ J 56: 847-854, 1992.
54. Takase H, Moreau P, and Luscher TF. Endothelin receptor subtypes in small arteries. Studies with FR139317 and bosentan. Hypertension 25: 739-743, 1995.
55. Teerlink JR, Loffler BM, Hess P, Maire JP, Clozel M, and Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 90: 2510-2518, 1994.
56. Tsutamoto T, Wada A, Hisanaga T, Maeda K, Ohnishi M, Mabuchi N, Sawaki M, Hayashi M, Fujii M, and Kinoshita M. Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol 33: 530-537, 1999.
57. Tsutamoto T, Wada A, Maeda Y, Adachi T, and Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 23: 1427-1433, 1994.
58. Verhaar MC, Strachan FE, Newby DE, Cruden NL, Koomans HA, Rabelink TJ, and Webb DJ. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97: 752-756, 1998.
59. Vierhapper H, Wagner O, Nowotny P, and Waldhausl W. Effect of endothelin-1 in man. Circulation 81: 1415-1418, 1990.
60. Wada A, Tsutamoto T, Fukai D, Ohnishi M, Maeda K, Hisanaga T, Maeda Y, Matsuda Y, and Kinoshita M. Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. J Am Coll Cardiol 30: 1385-1392, 1997.
61. Wade OL, Combes B, Childs AW, Wheeler HO, Cournard A, and Bradley SE. The effect of exercise on the splanchnic blood flow and splanchnic blood volume in normal man. Clin Sci 15: 457-463, 1956.
62. Waite RP and Pang CC. The sympathetic nervous system facilitates endothelin-1 effects on venous tone. J Pharmacol Exp Ther 260: 45-50, 1992.
63. Wang X, Douglas SA, Louden C, Vickery-Clark LM, Feuerstein GZ, and Ohlstein EH. Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 78: 322-328, 1996.
64. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, and Burnett JC Jr. Endothelin in human congestive heart failure. Circulation 89: 1580-1586, 1994.
65. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.